TY  - JOUR
AU  - Grande, Enrique
AU  - Rodriguez-Antona, Cristina
AU  - López, Carlos
AU  - Alonso-Gordoa, Teresa
AU  - Benavent, Marta
AU  - Capdevila, Jaume
AU  - Teulé, Alex
AU  - Custodio, Ana
AU  - Sevilla, Isabel
AU  - Hernando, Jorge
AU  - Gajate, Pablo
AU  - Molina-Cerrillo, Javier
AU  - Díez, Juan José
AU  - Santos, María
AU  - Lanillos, Javier
AU  - García-Carbonero, Rocío
PY  - 2021
DO  - 10.1002/onco.13885
UR  - http://hdl.handle.net/10668/18059
T2  - The oncologist
AB  - Sunitinib (SUN)-induced hypoxia within the tumor could promote the activation of the prodrug evofosfamide (EVO), locally releasing the cytotoxic DNA alkylator bromo-isophosphoramide mustard. SUNEVO, a phase II, open-label, single-arm trial,...
LA  - en
KW  - Biomarkers
KW  - Evofosfamide
KW  - Pancreatic neuroendocrine tumor
KW  - Safety
KW  - Sunitinib
KW  - Humans
KW  - Middle Aged
KW  - Neoplasms, Second Primary
KW  - Nitroimidazoles
KW  - Pancreatic Neoplasms
KW  - Phosphoramide Mustards
KW  - Progression-Free Survival
KW  - Sunitinib
TI  - Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
TY  - research article
VL  - 26
ER  -